According to the pharmaceutical industry on the 26th, some of the 18 items that Celltrion acquired from Takeda last year are still being sold under the name of Takeda. This is because the license right in Korea has not yet been completely transferred to Celltrion.

Celltrion acquired the rights of 18 items for chronic disease treatment and OTC drugs from Takeda in December of last year in the Asia-Pacific region for $278.3 million (approximately ₩307.4 billion). Celltrion Pharmaceuticals in Korea and Celltrion Healthcare in the rest of the world exercise their rights.

The main products are Nesina, a diabetes treatment drug based on DPP-4 inhibitor ,Actos, a diabetes treatmen